FDA drug approval timelines extend by 20% from current levels by 2027-06-30
user-generated· regulatory
FDA drug approval timelines extend by 20% from current levels by 2027…
Market overview
Uncertainty from Makary's departure will delay streamlined clinical trial processes and increase internal vacancies, prolonging review periods. Industry lobbying and political jockeying will exacerbate these delays.
regulatory prediction market
- Implied probability (Yes)
- 75%
- Closes
- 2027-12-31
Source: user-generated
More regulatory markets
- A national regulator mandates new cockpit security rules — 61% Yes
- Mail-in ballots will remain unrestricted for 2026 midterms — 75% Yes
- US state passes auto data privacy law — 65% Yes
- NATO approves $40B counter-drone program by Dec 2026 — 82% Yes
- NATO approves joint economic sanctions on Iran by 2026-12-31 — 60% Yes
- Nigerian Senate approves budget clarification probe by December 2026 — 75% Yes
- Iraq secures 10% higher OPEC+ quota by 2026-12-31 — 68% Yes
- Lyzr closes Series B at $500M valuation by 2026-12-31 — 80% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…